Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Mantle-Cell | 4 | 2022 | 32 | 0.690 |
Why?
|
| Adenine | 6 | 2022 | 120 | 0.370 |
Why?
|
| Pyrazoles | 5 | 2022 | 333 | 0.360 |
Why?
|
| Piperidines | 6 | 2022 | 235 | 0.340 |
Why?
|
| Pyrimidines | 5 | 2022 | 418 | 0.340 |
Why?
|
| Lymphoma, Follicular | 2 | 2021 | 30 | 0.320 |
Why?
|
| Ifosfamide | 1 | 2023 | 35 | 0.200 |
Why?
|
| Musculoskeletal Pain | 1 | 2022 | 16 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 153 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 175 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2021 | 216 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2018 | 200 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1297 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1342 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1163 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 808 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 605 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1824 | 0.090 |
Why?
|
| Rituximab | 2 | 2023 | 168 | 0.090 |
Why?
|
| Recurrence | 2 | 2021 | 1470 | 0.060 |
Why?
|
| Carboplatin | 1 | 2023 | 85 | 0.050 |
Why?
|
| Etoposide | 1 | 2023 | 121 | 0.050 |
Why?
|
| Biological Factors | 1 | 2022 | 27 | 0.050 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2022 | 15 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2022 | 22 | 0.050 |
Why?
|
| Myalgia | 1 | 2022 | 11 | 0.050 |
Why?
|
| Guanylate Cyclase | 1 | 2021 | 35 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2022 | 166 | 0.050 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 42 | 0.050 |
Why?
|
| Arthralgia | 1 | 2022 | 68 | 0.040 |
Why?
|
| Remission Induction | 1 | 2022 | 307 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 20 | 0.040 |
Why?
|
| Sirolimus | 1 | 2022 | 240 | 0.040 |
Why?
|
| India | 1 | 2021 | 238 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2021 | 617 | 0.040 |
Why?
|
| Humans | 8 | 2023 | 132061 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1573 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 438 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 206 | 0.030 |
Why?
|
| Adult | 3 | 2022 | 31568 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2224 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 2192 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1977 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 21406 | 0.020 |
Why?
|
| Child | 2 | 2023 | 25789 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1658 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5409 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 5009 | 0.020 |
Why?
|
| Young Adult | 1 | 2023 | 9957 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6229 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7102 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13064 | 0.010 |
Why?
|
| Adolescent | 1 | 2023 | 20562 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17419 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 13028 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 28964 | 0.010 |
Why?
|
| Male | 1 | 2018 | 64922 | 0.010 |
Why?
|
| Female | 1 | 2018 | 70712 | 0.010 |
Why?
|